Literature DB >> 9820617

Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma.

H J Karga1, M K Karayianni, D A Linos, S C Tseleni, K D Karaiskos, P D Papapetrou.   

Abstract

The RET proto-oncogene has been identified as the multiple endocrine neoplasia type 2 disease gene. An association between specific RET mutation and disease phenotype has been reported. We present the phenotype-genotype of 12 Greek families with multiple endocrine neoplasia type 2A (MEN 2A) or familial medullary thyroid carcinoma (FMTC). Seventy members were studied and DNA analysis for RET mutations was performed in fifty-eight of them. Exons 10, 11, 13, 14 and 16 of the RET proto-oncogene were analyzed by single strand conformation polymorphism analysis, direct DNA sequencing and/or restriction enzyme analysis. No mutations of the RET proto-oncogene were identified in 1 of 9 families with MEN 2A and in the 3 families with FMTC. In 7 MEN 2A families, the mutation was demonstrated in codon 634 and in 1 family it was demonstrated in codon 620. There was a low frequency, about 8%, of hyperparathyroidism associated with MEN 2A. The specific causative mutations for pararthyroid disease were C634R or C634Y. Among the MEN 2A individuals there was one case with de novo C634R mutation and one case, C634Y, with cutaneous lichen amyloidosis which predated by 24 years the diagnosis of MEN 2A. In 2 children who were MEN 2A gene carriers, microscopic medullary thyroid carcinomas were found. These data show a low frequency of hyperparathyroidism in our cases and provide further evidence that individuals with C634R as well as with C634Y mutations of the RET proto-oncogene could be at risk for parathyroid disease. Cutaneous lichen amyloidosis could be an early feature of MEN 2A. Additionally, direct DNA testing provided an opportunity to resect medullary thyroid carcinoma at an early stage.

Entities:  

Mesh:

Year:  1998        PMID: 9820617     DOI: 10.1530/eje.0.1390410

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

1.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 2.  MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics.

Authors:  Jessica Oliboni Scapineli; Lucieli Ceolin; Márcia Khaled Puñales; José Miguel Dora; Ana Luiza Maia
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 3.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 4.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

5.  Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.

Authors:  Junyi Wang; Bin Zhang; Wensheng Liu; Yongxia Zhang; Xuebing Di; Yanmei Yang; Dangui Yan
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

6.  Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.

Authors:  Beatriz González-Yebra; María Elena Medrano; Alejandra Mantilla; Virginia Palma; Carmen Colin; Dulce María Hernández; José Tapia; Brian Dawson; Mauricio Salcedo
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

7.  RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Authors:  Xiao-Ping Qi; Jian-Qiang Zhao; Zhen-Guang Chen; Jin-Lin Cao; Juan Du; Nai-Fang Liu; Feng Li; Mao Sheng; Er Fu; Jian Guo; Hong Jia; Yi-Ming Zhang; Ju-Ming Ma
Journal:  Oncotarget       Date:  2015-10-20

Review 8.  5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Authors:  Shu-Yuan Li; Yi-Qiang Ding; You-Liang Si; Mu-Jin Ye; Chen-Ming Xu; Xiao-Ping Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

9.  Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe.

Authors:  Maria Alevizaki
Journal:  Thyroid Res       Date:  2013-03-14

10.  The RET C611Y mutation causes MEN 2A and associated cutaneous

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Li Zao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.